A review article: Sevelamer hydrochloride and metabolic acidosis in dialysis patients

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 8, Issue 4, 2008, Pages 283-286

  Oka, Yoshinari ^a   Miyazaki, Masashi ^a   Takatsu, Shigeko ^a   Oohara, Toshiaki ^b   Toda, Keisuke ^b   Uno, Futoshi ^b   Matsuda, Hiroaki ^b  

^a Saiwai cho Memorial Hospital   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Bicarbonate; Dialysis; Dose depending; Metabolic acidosis; Prognosis; Sevelamer hydrochloride

Indexed keywords

ANION EXCHANGE RESIN; BICARBONATE; CALCIUM CARBONATE; CARBON DIOXIDE; CHLORIDE; LANTHANUM CARBONATE; PHOSPHATE BINDING AGENT; PLACEBO; SEVELAMER; SEVELAMER CARBONATE; UNCLASSIFIED DRUG; CHELATING AGENT; CHLORINE; POLYAMINE;

BICARBONATE BLOOD LEVEL; BONE DISEASE; BONE METABOLISM; CARBON DIOXIDE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DISEASE CONTROL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; HEALTH SURVEY; HEMODIALYSIS PATIENT; HUMAN; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERVENTILATION; METABOLIC ACIDOSIS; MORTALITY; PERITONEAL DISEASE; PH MEASUREMENT; PROGNOSIS; REVIEW; RISK REDUCTION; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; SUDDEN DEATH; SYMPTOM; TREATMENT DURATION; ACIDOSIS; BLOOD; DOSE RESPONSE; METABOLISM; RENAL REPLACEMENT THERAPY; RISK FACTOR;

ACIDOSIS; BICARBONATES; CARDIOVASCULAR DISEASES; CHELATING AGENTS; CHLORINE; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; POLYAMINES; RENAL DIALYSIS; RISK FACTORS;

EID: 60549096467     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152908786786197     Document Type: Review

References (30)

1. Edmung, G.; Lowrie, E.G.; Lew, N.L. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am. J. Kidney Dis., 1990, 15, 458-482.
2. Block, G.A.; Hulbert-Shearon, T.E.; Levin, N.W.; Port, F.K. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am. J. Kidney Dis., 1998, 31, 607-617.
3. Guérin, A.P.; London, G.M.; Marchais, S.J.; Metivier, F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol. Dial. Transplant., 2000, 15, 1014-1021.
4. Goodman, W.G.; Goldin, J.; Kuizon, B.D.; Yoon, C.; Gales, B.; Sider, D.; Wang, Y.; Chung, J.; Emerick, A.; Greaser, L.; Elashoff, R.M.; Salusky, I.B. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med., 2000, 342, 1478-1483.
5. Chertow, G.M.; Burke, S.K.; Raggi, P. Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int., 2002, 62, 245-252.
6. Chertow, G..M.; Raggi, P.; McCarthy, J.T.; Schulman, G.; Silberzweig, J.; Kuhlik, A; Goodman, W.G.; Boulay, A; Burke, S.K.; Toto, R.D. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am. J. Nephrol., 2003, 23, 307-314.
7. Chertow, G..M.; Raggi, P.; Chasan-Taber, S.; Bommer, J.; Holzer, H.; Burke, S.K. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol. Dial. Transplant., 2004, 19, 1489-1496.
8. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis., 2003, 42, 12-28.
9. Bommer, J.; Locatelli, F.; Satayathum, S.; Keen, M.L.; Goodkin, D.A.; Saito, A.; Akiba, T.; Port, F.K.; Young, E.W. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis., 2004, 44, 661-671.
10. Marco, M.P.; Muray, S.; Betriu, A.; Craver, L.; Belart, M.; Fernandez, E. Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients. Nephron, 2002, 92, 499-500.
11. Gallieni, M.; Cozzolino, M.; Brancaccio, D. Transient decrease of serum bicarbonate levels with Sevelamer hydrochloride as the phosphate binder. Kidney Int., 2000, 57, 1776-1777.
12. Qunibi, W.Y.; Hootkins, R.E.; McDowell, L.L.; Meyer, M.S.; Simon, M.; Garza, R.O.; Pelham, R.W.; Cleveland, M.V.; Muenz, L.R.; He, D.Y.; Nolan, C.R. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int., 2004, 65, 1914-1926.
13. Brezina, B.; Qunibi, W.Y.; Nolan, C.R. Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int., 2004, 66, 39-45.
14. Sonikian, M.A. Pani, I.T. Iliopoulos, A.N. Koutala, K.G, Marioli, S.I, Vlassopoulos, D.A. Metabolic acidosis aggravation and hyperkaliemia in hemodialysis patients treated by sevelamer hydrochloride. Ren. Fail., 2005, 27, 143-147.
15. Sonikian, M.; Metaxaki, P.; Vlassopoulos, D.; Iliopoulos, A.; Marioli, S. Long-term management of sevelamer hydrochloride-induced metabolic acidosis aggravation and hyperkalemia in hemodialysis patients. Ren. Fail., 2006, 28, 411-418.
16. Ramos, R.; Moreso, F.; Borras, M.; Ponz, E.; Buades, J.M.; Teixidó, J.; Morey, A.; Garcia, C.; Vera, M.; Doflate, M.T.; de Arellano, M.R.; Barbosa, F.; González, M.T. Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study. Perit. Dial. Int., 2007, 27, 697-701.
17. Oka, Y.; Miyazaki, M.; Takatsu, S.; Kunitomo, K.; Uno, F.; Maruyama, M.; Matsuda, H. Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage. Ther. Apher. Dial., 2007, 11, 107-113.
18. Nakai, S.; Wada, A.; Kitaoka, T.; Shinzato, T.; Nagura, Y.; Kikuchi, K.; Masakane, I.; Shinoda, T.; Yamazaki, C.; Sakai, R.; Marubayashi, S.; Morita, O.; Iseki, K.; Usami, T.; Kimata, N.; Suzuki, K.; Tabei, K.; Fushimi, K.; Miwa, N.; Yauchi, M.; Wakai, K.; Akiba, T. An overview of regular dialysis treatment in Japan (as of 31 December 2004). Ther. Apher. Dial., 2006, 10, 476-497.
19. Manns, B.; Stevens, L.; Miskulin, D.; Owen, W.F.; Jr, Winkelmayer, W.C.; Tonelli, M. A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney. Int., 2004, 66, 1239-1247.
20. Tonelli, M.; Wiebe, N.; Culleton, B.; Lee, H.; Klarenbach, S.; Shrive, F.; Manns, B. Alberta Kidney Disease Network. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol. Dial. Transplant., 2007, 22, 2856-2866.
21. Block, G.A.; Raggi, P.; Bellasi, A.; Kooienga, L.; Spiegel, D.M. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int., 2007, 71, 438-441.
22. McFarlane, P. A. Sevelamer and extension studies. Kidney Int., 2007, 72, 225-226.
23. Badve, S. V. Magner PO. Does Sevelamer reduce mortality by slowing of progression of coronary calcification? Kidney Int., 2007, 71, 1328-1329.
24. Nguyen, Q.V.; Descombes, E. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. No good evidence to promote a general use of sevelamer. Kidney Int., 2008, 73, 238-239,
25. Suki, W.N.; Zabaneh, R.; Cangiano, J.L.; Reed, J.; Fischer, D.; Garrett, L.; Ling, B.N. Chasan-Taber, S. Dillon, M.A. Blair, A.T. Burke, S.K. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int., 2007, 72, 1130-1137.
26. St Peter, W.L.; Liu, J.; Weinhandl, E.; Fan, Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am. J. Kidney Dis., 2008, 51, 445-454.
27. Akatsuka, T.; Mochizuki, T.; Koike, T. Buffering effects of calcium carbonate as clarified by sevelamer hydrochloride monotherapy. Ther. Apher. Dial., 2008, 12, 216-225.
28. Lindley, E.; Tattersall, J.; Wright, M. Correction of metabolic acidosis after conversion from sevelamer hydrochloride to lanthanum carbonate. NDT Plus 2008, 1, 196.
29. Delmez, J.; Block, G.; Robertson, J.; Chasan-Taber, S.; Blair, A.; Dillon, M.; Bleyer, A. J. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin. Nephrol., 2007, 68, 386-391.
30. Kazama, J. J. Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism. Ther. Apher. Dial., 2007, 11, S44-47.